<DOC>
	<DOCNO>NCT01042041</DOCNO>
	<brief_summary>RATIONALE : Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . PURPOSE : This phase I trial study side effect best dose sorafenib tosylate give together chemoembolization treat patient unresectable liver cancer .</brief_summary>
	<brief_title>Sorafenib Tosylate Chemoembolization Treating Patients With Unresectable Liver Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To evaluate toxicity safety integrate sorafenib chemoembolization unresectable hepatocellular carcinoma . SECONDARY OBJECTIVE : I . To observe image response ( AASLD/EASL modification RECIST ) time progression follow chemoembolization conjunction sorafenib . OUTLINE : Patients receive oral sorafenib tosylate twice daily . Beginning 2 week later , patient undergo chemoembolization cisplatin , doxorubicin hydrochloride , mitomycin C. Chemoembolizaton repeat month 4 procedure absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week every 3 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Histologically confirm hepatocellular carcinoma AND/OR Magnetic Resonance Imaging ( MRI ) Computerized Tomography ( CT ) consistent liver cirrhosis AND least one solid liver lesion &gt; 2cm arterialphase enhancement delay washout regardless alphafeto protein level ( AFP ) AND/OR AFP &gt; 400ng/mL AND evidence least one solid liver lesion &gt; 2cm regardless specific image characteristic CT MRI Patient candidate transplantation , resection , ablation ; intend therapy chemoembolization Patient meet clinical criterion treatment chemoembolization Absolute contraindication chemoembolization include uncorrectable bleed disorder , uncorrectable contrast sensitivity , leukopenia ( white blood cell count &lt; 1000/uL ) , cardiac renal insufficiency ( serum creatinine &gt; 2.0mg/dL ) , hepatic encephalopathy , jaundice , dilate intrahepatic bile duct Portal vein occlusion relative contraindication chemoembolization perform collateral vessel hepatopedal flow demonstrate angiographically Hepatic compromise determine follow combination parameter contraindication therapy : lactate dehydrogenase &gt; 425 U/L , aspartate aminotransferase &gt; 100 U/L , total bilirubin &gt; 2.0 mg/dL &gt; 50 % liver volume replace tumor Patients may treat ablation resection past , sooner 4 week study registration Patients may NOT previously treat sorafenib , chemoembolization , radioembolization , systemic chemotherapy cytotoxic agent molecularly target agent ECOG performance status = &lt; 2 Life expectancy great 3 month Platelets &gt; = 50,000/mcL Total bilirubin = &lt; 2.0 mg/dl AST ( SGOT ) /ALT ( SGPT ) = &lt; 3X institutional upper limit normal Creatinine = &lt; 1.5 mg/dl INR = &lt; 1.5 Patients must clinical sign heart failure meet New York Heart Association functional classification I II define : Class I Patients limitation activity ; suffer symptom ordinary activity ; Class II Patients slight , mild limitation activity ; comfortable rest mild exertion Because agent used trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Should woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Exclusion Patients may receive investigational agent History allergic reaction attribute compound similar chemical biologic composition sorafenib History radiologic contrast reaction control standard premedications Patients must take cytochrome P450 enzyme induce drug Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled hypertension , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study Breastfeeding discontinue Prophylactic use GCSF GMCSF permit trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>